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Abstract
Background: Virus-like particle (VLP) technology is considered one of the most promising approaches in animal
vaccines, due to the intrinsic immunogenic properties as well as high safety profile of VLPs. In this study, we
developed a VLP vaccine against infectious bursal disease virus (IBDV), which causes morbidity and mortality in
chickens, by expressing a baculovirus in insect cells.
Methods: To improve the self-proteolytic processing of precursor polyprotein (PP), we constructed a recombinant
baculovirus transfer vector that co-expresses PP and the VP4 protease gene of IBDV.
Results: Expression and VLP assembly of recombinant proteins and antigenicity of the VLP were examined by Western
blotting, ELISA, and transmission electron microscopy. In animal experiments, vaccination with the recombinant VLP
induced strong and uniform humoral immunity and provided complete protection against challenge with very virulent
(vv) IBDV in SPF chickens (n = 12). As determined by the bursa of Fabricius (BF)/body weight (B/BW) ratio, the
protection against post-challenge bursal atrophy was significantly higher (P < 0.001) in VLP-vaccinated birds
than in non-vaccinated controls.
Conclusions: Since the protective efficacy of the VLP vaccine was comparable to that of a commercially available
inactivated vaccine, the recombinant VLP merits further investigation as an alternative means of protection against vvIBD.
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Background
Infectious bursal disease virus (IBDV) causes clinical signs,
severe immunosuppression, and ultimately death in young
chickens less than 6 weeks old. In particular, it destroys
immune cells within the bursa of Fabricius (BF), resulting
in decreased immune response to secondary infections and
to vaccines for other diseases. IBDV belongs to the genus
Avibirnavirus of the family Birnaviridae, whose members
contain two double-stranded RNA genome segments (A
and B) [1]. Genome segment B (approximately 2.9 kb)
encodes viral protein 1 (VP1), the RNA-dependent RNA
polymerase (RdRp) [2]. Genome segment A (approximately
3.3 kb) has two open reading frames (ORFs). The smaller
ORF of the segment is approximately 400 bp long and
encodes VP5 [3]. The larger ORF is approximately 3 kb in
length and encodes precursor polyprotein (PP) with a
molecular mass of 109 kDa. Nascent PP is cleaved into the
individual viral proteins VP2, VP3, and VP4 [4]. VP2, in
particular, is highly conformation-dependent with neutraliz-
ing epitopes [5–7], and so plays an important role in indu-
cing protective immunity in the host [8–10].
In the global poultry industry, the control of IBDV is
based mainly on the immunization of chickens with live,
inactivated, or recombinant vaccines [11]. Traditionally,
breeder flocks are immunized with an oil-emulsion inac-
tivated IBDV vaccine after priming with live IBDV vac-
cines. This strategy gives protective passive immunity to
the newly hatched chicks during the first few weeks of
life. In many cases, oil-emulsion inactivated vaccines are
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manufactured using BF-derived IBDV antigen extracted
from specific pathogen-free (SPF) chicks infected with
virulent IBDV, since it is considered to be more im-
munogenic than egg-based or cell culture-based IBDV
antigen. However, this process is time-consuming and
requires the handling of infectious virus and a large
number of SPF animals.
To overcome these limitations, various approaches for
producing recombinant IBDV proteins in vitro have been
developed to create alternative vaccines to the killed IBDV
vaccine. Subunit vaccines carrying the protective VP2 of
IBDV have been developed using recombinant proteins or
vectored viruses including E. coli [12, 13], yeast [14–17],
adenovirus [18], fowlpox virus [19], baculovirus [10, 20, 21],
vaccinia virus [22], herpesvirus [23] and even plants
[24–26], which avoid the safety issues associated with
use of animals for vaccine production. However, the
protection afforded by the VP2 vaccine tends to vary
depending on the expression system employed and only a
limited number of VP2 vaccines have been commercialized.
One form of novel vaccine carrying protective viral
proteins is the virus-like particle (VLP). VLPs are assem-
bled from viral structural proteins and resemble the
structure of an authentic viral particle but are devoid of
any genetic material. Therefore, recombinant vaccines
based on VLP technology hold great promise for the de-
velopment of highly efficacious vaccines that could replace
inactivated vaccines directed against several pathogenic
viruses of human and animals [27–30].
Regarding IBDV, one strategy for producing VLPs is
the expression of PP, where the VP4 protease drives the
maturation process of VP2 and VP3, which self-
assemble into VLPs [20, 22, 31, 32]. However, the pro-
duction of VLPs resembling authentic IBDV has proved
to be unsatisfactory due to inefficient processing and
maturation [31–34]. Another approach involves the co-
expression of two structural proteins pVP2 and VP3
using two different recombinant baculoviruses [34–36],
but a precise adjustment of the MOI for both viruses is
required for efficient assembly of the VLPs [37].
Previously, we succeeded in producing swine vesicular
disease virus VLPs by use of a single recombinant
baculovirus bi-directionally expressing the viral protease
(3CD) and structural precursor protein (P1) [38]. In this
study, we applied similar strategy to produce IBDV VLPs
by bi-directional co-expression of PP and viral protease
VP4, which has not been attempted for IBDV. The
expressed proteins were examined for morphology, anti-
genicity, immunogenicity, and protective efficacy.
Materials and methods
Virus
IBDV strain Kr/LC/2010 (LC10), kept in our laboratory,
was used as a genetic template to obtain viral RNA or as
a challenge virus for protection efficacy tests. LC10 is a
very virulent IBDV (vvIBDV) isolated from a Korean
broiler farm that had had an IBD outbreak in 2010. The
virus was propagated in 9-day-old embryonated chicken
eggs from SPF hens. The viral titer was expressed as
50 % embryo infective dose (EID50).
Construction of a baculovirus transfer vector
The strategy for amplifying of the PP and VP4 genes of
IBDV is outlined in Fig. 1a. Viral genomic RNA was
extracted from LC10 using an RNeasy Mini kit (Qiagen,
USA) and the PP and VP4 genes were separately amplified
using an OneStep RT-PCR kit (Qiagen) according to the
manufacturer’s instructions. Two PCR primer sets were
designed to amplify the full-length ORFs of PP gene
(3039 bp in length) and VP4 gene (813 bp in length),
respectively (Table 1). Restriction enzyme sites were incor-
porated at the 5′ ends of the primers to facilitate cloning.
The PCR products were purified and cloned separately into
pGEM-T Easy (Promega). Then, the PP and VP4 inserts
were excised from the vectors using restriction enzymes
EcoR I and Hind III, and Nhe I and Kpn I, respectively,
and both were sub-cloned into pFastBacDual vector
(Invitrogen), where the PP gene was inserted downstream
of the polyhedron promoter (PPH) and the VP4 gene was
placed downstream of the Pp10 promoter. For comparison
purposes, the PP gene alone was inserted downstream of
PPH of pFastBac1 vector (Invitrogen). The resulting trans-
fer plasmids containing both genes (PP and VP4) or the
PP gene alone were designated pFastBac-PP/VP4 and
pFastBac-PP, respectively (Fig. 1b).
Rescue of recombinant baculoviruses
Recombinant baculovirus was generated using the Bac-
to-Bac expression system (Invitrogen). Briefly, a recom-
binant DNA bacmid containing the PP and VP4 genes
(bacmid-PP/VP4) was generated by transforming com-
petent DH10Bac E. coli cells (Invitrogen) with the
pFastBac-PP/VP4 according to the manufacturer’s in-
structions. The bacmid-PP/VP4 was then transfected
into Spodoptera frugiperda 9 (Sf9) cells (2 × 106 cells/ml)
supplemented with Sf900 II medium (Gibco) in 6-well tis-
sue culture plates. After 72 h incubation at 27 °C, the cul-
ture supernatants were subjected to a plaque assay to
isolate recombinant baculovirus co-expressing PP and
VP4 genes (rBac-PP/VP4). The presence of two inserts in
the rBac-PP/VP4 was confirmed by PCR using the primer
pairs described above. The positive plaque clone was des-
ignated rBac-PP/VP4. For comparison, a recombinant
DNA bacmid containing the PP gene alone (bacmid-PP)
and a recombinant baculovirus expressing PP alone
(rBac-PP) were also generated using the pFastBac-PP in
the same way as above. The recovered baculovirus prepa-
rations were stored at 4 °C.
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Preparation of recombinant proteins
Sf9 cells (5 × 105 cells/ml) were seeded in a spinner
flask (200 ml) containing Sf900II medium and were
infected with rBac-PP/VP4 at a MOI of 1. Following a
3 day incubation, the infected cells were collected and
precipitated by low-speed centrifugation (2,000 x g,
20 min). The cell pellets were re-suspended in 1/20 vol-
ume of ice-cold lysis buffer (10 mM Tris, 130 mM
NaCl, 1 % (v/v) Triton X-100, pH 7.5) containing a prote-
ase inhibitor cocktail (BD Biosciences, USA), sonicated
briefly with three 5 s pulses (Soniprep 150, MSE Sanyo,
Japan), and clarified by high-speed centrifugation (11,650
x g, 35 min). The clarified supernatant was used as a
recombinant antigen in this study. Recombinant proteins
from rBac-PP were produced in the same manner.
Western blotting
Expression of IBDV proteins in VLPs was confirmed by
Western blotting. Briefly, proteins were separated on 10 %
SDS-PAGE gels and blotted onto PVDF membranes (Life
Technologies, USA). Membranes were incubated with anti-
IBDV serum from chickens that had been immunized with
purified, inactivated LC10. After several washes with 0.05 %
Tween 20 in phosphate-buffered saline (PBS), bound anti-
bodies were visualized by the use of alkaline phosphatase-
conjugated goat anti-chicken IgG (H + L) (KPL, USA) and
BCIP/NBT phosphatase substrate (KPL, USA).
Double antibody sandwich enzyme-linked immunosorbent
assay (DAS-ELISA)
For antigen quantification and to compare the antigenic-
ity of the recombinant VP2 protein, we performed DAS-
ELISA as described previously [39]. Briefly, MaxiSorp
ELISA plates (Nunc) were coated with 50 μl of anti-
VP2 monoclonal antibody (MAb) R63 [40] at the opti-
mal concentration (4 μg/ml) in 0.01 M PBS at 37 °C for
1 h with constant shaking. The plates were washed
Table 1 Primers used in this study
Genes Primer name Sequencea
Precursor
polyprotein (PP)
LCPP-F 5′-CGG AAT TCC Gat gGAC AAA CCT
GCA AGA TC-3′
LCPP-R 5′-CCA AGC TTG GTC ACT CAA GGT
CCT CAT-3′
VP4 LCVP4-F 5′-CGG CTA GCC Gat gAG GAT AGC
TGT G-3′
LCVP4 5′-GGG GTA CCC CTC ATT TGA TAA
ACG TCG C-3′
aLower case letters indicate ATG codons. Underlined sequences indicate the
restriction enzyme sites
Fig. 1 Strategy for construction of recombinant baculovirus transfer vector. a A schematic representation of the IBDV segment A showing regions
amplified (solid lines) and primer positions (arrows). Amplification of PP and VP4 genes of IBDV was performed by RT-PCR. b Construction of a recombinant
single (pFastBac-PP) or dual (pFastBac-PP/VP4) expression vector containing the PP and VP4 genes of IBDV. c A schematic of the strategy used
for the production of VLP antigen induced by recombinant baculovirus Bac-PP/VP4 in Sf9 cells
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three times with PBS containing 0.05 % Tween 20
(PBST) and then incubated with 50 μl of IBDV or VLP
antigens for 1 h at 37 °C. Following a washing step, the
plates were incubated for 1 h at 37 °C with 50 μl of
anti-IBDV chicken sera (for VP2 quantification) or 10
chicken sera with various titers (for antigenic compari-
son) in blocking buffer (PBS containing 0.02 % Tween
20 and 1 % skimmed milk). To enable comparisons of
antigenicity, SPF chicken sera and anti-IBDV chicken
sera were also tested as a negative control and as a
positive control, respectively. Following an additional
washing step, the plates were incubated with
peroxidase-conjugated goat anti-chicken IgG (H + L)
for 1 h at 37 °C. After the final wash, the plates were
incubated with 50 μl of tetramethylbenzidine (TMB)
substrate solution (KPL, USA) for 10 min. The color
development was stopped by 50 μl of 1 N HCl solution.
The optical density (OD) was measured at 450 nm
using an automatic ELISA reader (Tecan, Austria). For
antigenic comparisons, data were normalized against
those of negative sera and expressed as signal-to-positive
(S/P) ratios using the formula (ODsample – ODnegative)/
(ODpositive – ODnegative)x1000.
Transmission electron microscopy
The rBac-PP/VP4-derived recombinant protein samples
were purified by sucrose density gradient ultracentrifuga-
tion (89,454 x g, 6 h). The resulting fractions were fixed
with 2.5 % glutaraldehyde in PBS (pH 7.2) and post-fixed
in a solution of 1 % osmium tetroxide in PBS at 4 °C for
2 h. After dehydration in a graded series of ethanol and
propylene oxide, the samples were embedded in spur
epoxy resin. Ultrathin sections were made and stained
with uranyl acetate and lead citrate, and were observed
under an H-7100FA transmission electron microscope
(Hitachi, Japan).
Preparation of a pilot IBDV VLP vaccine
The rBac-PP/VP4-derived recombinant protein was used to
make a pilot IBDV VLP vaccine. For this purpose, the re-
combinant protein was two-fold diluted and titrated using
a commercial IBDV immunochromatographic (IC) kit
(BioNote, Korea) with a detection limit for IBDV of
between 103.1 and 103.9 EID50/ml [41]. The IC unit was
the reciprocal of the highest dilution that gives a positive
signal for IBDV. The pilot VLP vaccine was prepared
by emulsifying 32 (25) IC units of the antigen with
Montanide ISA70 adjuvant (Seppic, France) at a ratio
of 30:70 (v/v).
Animal experimentation
A total of 36 SPF white leghorn chickens of 3 weeks of
age (Namduck Sanitec, Korea) were used in the study.
All animal procedures were approved and supervised
by the Institutional Animal Care & Use Committee
(IACUC) of the Animal and Plant Quarantine Agency
(QIA). A first group of 12 birds was vaccinated with
one dose of the pilot VLP vaccine (32 IC units in 0.5 ml
per bird) via intramuscular route. A second group of 12
birds was injected intramuscularly with one dose (0.5 ml)
of a commercial IBD vaccine (Nobilis IB + G +ND, MSD
Animal Health). Finally, a last group of 12 control birds
was injected with PBS. Blood samples were taken from all
birds on day 14 after vaccination, and IBDV-specific
serum antibodies were titrated with the use of IBD-XR
ELISA kit (IDEXX, USA) according to the manufacturer’s
instructions.
Two weeks after vaccination, all birds were challenged
with 104.5 EID50 (0.1 ml per bird) of vvIBDV LC10 strain
via the oral route. The birds were monitored daily for
overt clinical signs for 10 days after the challenge. Surviv-
ing birds were humanely sacrificed and examined the
presence of gross BF lesions. The BF and body weights of
each sacrificed bird were recorded. The BF/body weight
(B/BW) ratio was calculated as the BF weight (g)/body
weight (g) x 1,000. B/BW ratios < 2 were taken to indicate
bursal atrophy.
Statistical analyses
Statistical analysis was performed using GraphPad Instat
version 3.05 for Windows (GraphPad Software). A two-
tailed Fisher’s exact test was used to compare mortality,
Table 2 Protective efficacy of recombinant VLP vaccine against challenge with vvIBDV in 3-week-old SPF chickens compared with a
commercial inactivated vaccine or no vaccine (PBS treatment). Two weeks after immunization, birds were challenged with vvIBDV
LC10 strain orally (104.5EID50 per bird) and observed for 10 days
Vaccine Mortality, n (%) Clinical signs, na Gross lesions, nb Bursal atrophy, nc B/BW ratio, mean (SD)
Inactivated vaccine (n = 12) 0 (0)** 0*** 3** 3** 3.46 (1.42)*
VLP vaccine (n = 12) 0 (0)** 0*** 4* 3** 3.69 (1.74)**
Control (n = 12) 7 (58) 12 5 5 1.14 (0.30)
aNumber of birds with clinical signs, including depression, anorexia, diarrhea, and death
bNumber of surviving birds with gross lesions in the BF
cNumber of surviving animals with a B/BW ratio (bursal weight/body weight x 1000) lower than 2
*P < 0.1, ** P <0.01, *** P <0.001 compared with the non-vaccinated control group (Fisher’s exact test)
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clinical signs, the presence of gross lesions, and B/BW
ratios among groups. Differences in ELISA titer and mean
B/BW ratio between groups were analyzed by one-way
analysis of variance (ANOVA) with a Turkey-Kramer post
hoc test. Linear regression was used to determine the
strength of the correlation between the VLP antigen and
IBDV antigen. P values less 0.05 were considered to indi-
cate significance.
Results
Recombinant baculovirus containing the IBDV PP and VP4
genes
The PP and VP4 genes of IBDV were separately ampli-
fied and cloned into the pFastBacDual vector where they
were placed under control of two different promoters.
The recombinant baculovirus transfer vector was desig-
nated pFastBac-PP/VP4. For comparison purposes, the
PP gene alone was cloned into the pFastBac1 vector.
These constructs were confirmed to be in the correct
orientation and to contain uninterrupted ORFs by PCR
and sequencing (data not shown). pFastBac-PP/VP4 and
pFastBac-PP were used to transform E. coli for the pro-
duction of bacmids, which were then transfected into
Sf9 cells. The transfected cells showed typical cytopathic
effects, including low cell density, enlarged cells, and
poor adherence to the substrate. Recombinant baculo-
virus particles were recovered from Sf9 cells and con-
firmed by PCR (data not shown).
Analysis of expressed recombinant proteins
PP is known to be processed into VP2, VP3, and VP4
during viral replication in susceptible cells, and the
resulting VP2 and VP3 self-assemble to form virion
capsids (Fig. 1c). To investigate whether the rBac-PP/
VP4-expressed PP also splits into VP2, VP3, and VP4,
the recombinant proteins were biochemically analyzed.
For this purpose, Sf9 cells were infected with either
rBac-PP or rBac-PP/VP4 and recombinant proteins
were extracted after 72 h.
In Western blotting analysis, a faint protein band of
28 kDa, corresponding to VP4, was detected with anti-
IBDV chicken serum in rBac-PP/VP4 protein extracts
(Fig. 2a, right lane). Two bands of approximately 32 kDa
and 42 kDa, corresponding to VP3 and VP2, respectively,
were detected in both preparations, but the intensity of
both bands (especially VP3) was lower for rBac-PP (Fig. 2a,
left lane) than for rBac-PP/VP4. In DAS-ELISA, the yield
of VP2 from rBac-PP/VP4 was at least four-times higher
than that from rBac-PP (Fig. 2b). These findings indicate
that the expression of recombinant proteins by rBac-PP/
VP4 results in the cleavage of PP into VP2, VP3, and VP4,
and that the cleavage occurs more efficiently when PP and
VP4 are simultaneously expressed than when PP is
expressed alone.
To further investigate whether protein expression by
rBac-PP/VP4 results in VLP formation, we used transmis-
sion electron microscopy (TEM). TEM examination of
negatively stained protein preparations revealed the pres-
ence of numerous VLPs (Fig. 3). The VLPs had an authen-
tic IBDV structure in terms of morphology, and the size of
the particles was approximately 60 nm [42, 43]. No VLPs
were observed in extracts from non-transfected Sf9 cells
(data not shown).
DAS-ELISA was also used to investigate whether VLPs
are antigenically similar to IBDV. Ten chicken sera hav-
ing different antibody titers against IBDV were tested for
reactivity to both antigens at least three times. A strong
linear association (r2 = 0.9594, P < 0.001) was observed
for the reactivity between the parental LC10 strain and
recombinant VLP antigen (Fig. 4).
Fig. 2 Biochemical analysis of proteins expressed by the recombinant baculovirus. a Western blot analysis of VLP antigens: lane 1, VLP antigen
produced by rBac-PP; lane 2, VLP antigen produced by rBac-PP/VP4, b Antigenic reactivity of VLP antigens measured by DAS-ELISA. VLP antigens
produced by rBac-PP and rBac-PP/VP4 were independently applied to DAS-ELISA to compare their R63 MAb reactivity with the R63 MAb reactivity
of VP2 of IBDV. Serial dilution of VLP antigens were used to measure the titers of the expressed VP2 protein in VLPs
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Immune response to the pilot IBDV VLP vaccine
Then we investigated whether the VLP antigen provokes
a protective immune response in chickens. For this pur-
pose, a pilot IBDV VLP vaccine was formulated by emulsi-
fying the VLP antigen at a final concentration of 32 IC
units per dose in Montanide ISA70 adjuvant, pre-
determined minimal effective dose of protective antigen in
preliminary study. For comparison, a commercial inacti-
vated oil-emulsion IBDV vaccine was used. Prior to
immunization, all birds were found free of antibodies to
IBDV when tested by ELISA (data not shown). Two weeks
after a single immunization (Fig. 5), all 12 birds that had
received the pilot VLP vaccine showed seroconversion to
IBDV, with a mean ELISA titer of 4977 (SD = 993; range,
3259 to 7060). The commercial vaccine also induced an
immune response to IBDV, but four of 12 vaccinated birds
were still IBDV antibody-negative (ELISA titer, < 396).
The mean ELISA titer in this group (3203) was lower
than that achieved with the pilot VLP vaccine, and the
variation (SD = 3661) was greater. Control birds that re-
ceived only PBS remained IBDV antibody-negative dur-
ing the experiment.
To test the protective efficacy of the vaccine, the vacci-
nated birds were challenged with vvIBDV strain LC10
(104.5 EID50 per bird) after 2 weeks, and clinical signs
and mortality were observed for 10 days. As shown in
Table 2, all 12 control birds (treated just with PBS)
showed severe clinical signs such as depression, an-
orexia, and diarrhea, and 7 (58 %) died within 10 days.
Pathological examination revealed BF lesions, such as ca-
seous cores and petechial hemorrhage, and bursal atrophy.
In contrast, all 12 birds that had been vaccinated with the
pilot VLP vaccine showed no clinical signs and survived
the vvIBDV challenge. Pathological examination found no
gross lesions in the BF of eight of these birds (67 %), while
four did have bursal lesions, including bursal atrophy in
three animals. Similar results were obtained in the 12
birds vaccinated with the commercial IBDV vaccine: they
showed no clinical signs, and three birds had pathological
bursal lesions and bursal atrophy. Among them, one had
no detectable antibodies, while the other two had low level
of antibodies (ELISA titers < 1200).
Discussion
In this study, we employed a novel strategy to produce
VLPs based on a single recombinant baculovirus that
simultaneously expresses PP and VP4 under the control
of different promoters. Western blot analysis and DAS-
ELISA revealed that PP expressed by rBac-PP/VP4 and
rBac-PP was successfully split into structural proteins
VP2, VP3, and VP4. Notably, the yields of VP2 and VP3
were greater when VP4 was co-expressed with PP. Since
VP2 and VP3 are believed to form, respectively, the
Fig. 3 Electron microscopy of negatively stained recombinant VLPs
purified from Bac-PP/VP4 infected Sf9 cells. VLPs are indicated by black
arrows. Bar = 100 nm
Fig. 4 Correlation between recombinant VLP antigen reactivity and
IBDV antigen reactivity. Linear regression of the mean S/P ratios obtained
from the absorbance values of the reactivity of anti-VP2 MAb to wild
type parental IBDV (LC10) and recombinant VLP antigen. The solid line
represents the line of best fit
Fig. 5 Humoral immune response to IBDV after VLP vaccination in
chickens. Mean ELISA titers induced in SPF chickens after the injection of
VLP vaccine or a commercial inactivated IBD vaccine. Error bars. standard
deviations; dashed-line, cut-off titer (396). **p< 0.01 and ***p< 0.001 by
ANOVA with Tukey-Kramer post-test compared with the non-vaccinated
control group
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outer and inner layers of the virion in roughly equimolar
amounts [44, 45], increases in the concentration of both
proteins likely assist in forming VLPs. This was supported
by the TEM observation that rBac-PP/VP4-expressed pro-
teins formed VLPs with a diameter of 60 nm, resembling
authentic virus. Until now, however, PP expression alone
has often resulted in inefficient assembly of VLP and most
expressed proteins formed tubule-like structures instead of
VLPs [20]. Moreover, insect cells lack the puromycin-
sensitive aminopeptidase (PurSA) that, in host cells, is
involved with virus assembly [46]. Thus, PP expression
alone is inadequate to produce VLPs efficiently in complete
form. Nevertheless here we successfully produced VLPs
from PP expressed by recombinant baculovirus in insect
cells through co-expression of VP4 protease. Similarly, the
use of a highly productive baculovirus transfer vector
pAcYM1 also seems to be involved in enhanced assembly
efficiency of the VLPs [34]. Therefore, an increased yield of
VP4 possibly improves both the yield of VP2 and VP3 and
the efficiency of VLP formation. With the observation that
VP3 is crucial to the formation of a VLP [32], it can be also
suggested that the high VP3 expression in this study had a
positive impact on VLP formation.
It is known that the major neutralizing sites on VP2
are conformation-dependent, and that incorrect VP2
folding results in a lack of immunogenicity in chickens
[9, 20, 47]. This means that the immunogenicity and
protective capability of the VLP can be greatly affected
by antigenic structure of VP2 in VLPs. Recently, Jackwood
et al. [35] demonstrated that recombinant VLPs formed
by co-expression of VP2 and VP3 are more close in anti-
genic structure to naïve IBDV VP2 than to pVP2 alone
when analyzed using VP2-specific monoclonal antibodies.
The VLPs produced here also showed antigenicity close to
naïve IBDV when tested by DAS-ELISA and a commercial
IC kit. We postulate that co-expression of VP4 protease
with PP increased the yield of VP2 and VP3 by strength-
ening the proteolytic processing of IBDV PP, followed by
proper morphogenesis of the VLPs resulting from post-
translational modifications.
The VLP vaccine elicited a strong humoral immune
response and protected the chickens completely from
vvIBDV infection in SPF chickens, in contrast to previous
results where recombinant IBDV PP alone induced incom-
plete protection [20]. The difference might be due to the
correct assembly and antigenic structure of the VLPs
resembling authentic IBDV in our study. In part, baculo-
virus itself contained in the VLP vaccine of the study is
likely to enhance immunogenicity by activating local innate
immune response [48]. Besides, the normal poultry vaccine
program primes young birds with live attenuated IBDV
vaccines and then hyperimmunizes them with killed IBDV
vaccine several weeks before they lay in most breeder
farms. Therefore, it is necessary to determine whether the
combination of VLP vaccine with live attenuated vaccine
on the farm could provoke a more solid protective immun-
ity in breeder flocks than the VLP vaccine alone. If so, our
VLP vaccine could be an alternative to the commercial
killed IBDV vaccine (BF-derived IBDV antigen).
Moreover, genomic RNAs from vvIBDV were used as
the genetic source for the production of the VLPs, thus
the antigenic structure of our VLPs more likely resem-
bles vvIBDV than that of the current vaccine strain. If
this is true, VLP vaccination in breeder flocks could pro-
vide progeny chicks with efficacious protective immunity
via maternal-derived antibodies (MDAs), which are crit-
ical for early protection. The success of live attenuated
IBDV vaccination in young chicks with MDAs is greatly
affected by the degree of flock MDA uniformity as well
as MDA titers. MDA uniformity is the result of the
breeder’s immunity induced by IBDV vaccination, expos-
ure to field virus, immune suppression, and age of the
flock. In particular, the MDA uniformity of a flock is crit-
ical to determine the optimal timing and frequency of live
attenuated IBDV vaccination in young chicks. Practically,
a flock with poor MDA uniformity (e.g., a coefficient of
variation >80 %) requires a sophisticated and complicated
live attenuated IBDV vaccination program with several
vaccinations in order to protect birds from exposure to
vvIBDV [13, 49]. Thus, it is noteworthy that the VLP vac-
cine developed here induced a more uniform antibody
response in a flock than did the commercial killed IBDV
vaccine. If this finding is confirmed, breeder flocks vacci-
nated with the VLP vaccine will be able to confer uniform
MDA titers to progeny chicks, which would be an advan-
tage in deciding the optimal timing for IBD vaccination in
young offspring flocks.
Conclusions
To improve the self-proteolytic processing of PP of IBDV,
VP4 protease of IBDV were co-expressed with the PP in
insect cells by single recombinant baculovirus containing
the PP and VP4 protein genes. Simultaneous expression of
PP and VP4 protease recombinant proteins resulted in
increase in the yields of VP2 and VP3, thus possibly leading
to the efficient formation of VLPs morphologically and
antigenically similar to IBDV. In animal experiment, pro-
tective efficacy of our VLP vaccine was comparable to that
of the commercial killed IBDV vaccine. In conclusion, IBD
VLP vaccine in this study protects chickens from vvIBDV
that is possibly comparable to commercial vaccines and
possibly due to the presence of the additional VP4.
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